| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Stuart Cobb is Chief Scientific Officer at NGNE. Stuart Cobb's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $813K at current prices.
The NGNE filings lean toward selling, a net 6,797 shares.
Stuart Cobb has 3 Form 4 filings on record from March 2024 to March 2026, all as Chief Scientific Officer at Neurogene (NGNE), 2024–2026.
The 6 reported transactions were 3 open-market sales, 2 stock awards and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $141K.
The only open-market sale was 6,797 shares of NGNE at an average $20.81 on March 13, 2026, about $141K.